Video Series: Research, Webinars
Deepika Darbari, MD, reviews age-appropriate screenings and immunizations for children with sickle cell disease, as well as tips for co-managing the care of children with sickle cell disease.
Invest in future cures for some of life's most devastating diseases
For 45 years, clinicians around the nation have been offering the parents of pediatric patients diagnosed with diffuse intrinsic pontine glioma (DIPG) the same grim prognosis. Now, researchers at Children’s National are seizing the opportunity to change that narrative, by exploring the genetic mutations associated with this disease to unlock the possibility of new therapies.
David Jacobsohn, MD, ScM, discusses the various forms of blood and marrow transplantation as well as their efficacy in treating a range of diseases affecting children.
Children’s National is one of just a few hospitals with extensive experience in treating DIPG patients, as well as an active research program innovating new, more promising therapies for DIPG.
There are more than 300 cases in the U.S. each year, but its relative rarity actually makes fighting DIPG more challenging. There is little federal research funding for the study of “rare pediatric” diseases, and many oncologists don’t have specialized experience with DIPG or its treatments.